257 related articles for article (PubMed ID: 15279044)
1. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors.
Valenstein M; Blow FC; Copeland LA; McCarthy JF; Zeber JE; Gillon L; Bingham CR; Stavenger T
Schizophr Bull; 2004; 30(2):255-64. PubMed ID: 15279044
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission.
Valenstein M; Copeland LA; Blow FC; McCarthy JF; Zeber JE; Gillon L; Bingham CR; Stavenger T
Med Care; 2002 Aug; 40(8):630-9. PubMed ID: 12187177
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.
Valenstein M; Ganoczy D; McCarthy JF; Myra Kim H; Lee TA; Blow FC
J Clin Psychiatry; 2006 Oct; 67(10):1542-50. PubMed ID: 17107245
[TBL] [Abstract][Full Text] [Related]
4. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program.
Menzin J; Boulanger L; Friedman M; Mackell J; Lloyd JR
Psychiatr Serv; 2003 May; 54(5):719-23. PubMed ID: 12719504
[TBL] [Abstract][Full Text] [Related]
5. Treatment adherence with antipsychotic medications in bipolar disorder.
Sajatovic M; Valenstein M; Blow FC; Ganoczy D; Ignacio RV
Bipolar Disord; 2006 Jun; 8(3):232-41. PubMed ID: 16696824
[TBL] [Abstract][Full Text] [Related]
6. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension.
Piette JD; Heisler M; Ganoczy D; McCarthy JF; Valenstein M
Psychiatr Serv; 2007 Feb; 58(2):207-12. PubMed ID: 17287377
[TBL] [Abstract][Full Text] [Related]
7. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
[TBL] [Abstract][Full Text] [Related]
8. Factors related to antipsychotic oversupply among Central Texas Veterans.
Yang M; Barner JC; Worchel J
Clin Ther; 2007 Jun; 29(6):1214-25. PubMed ID: 17692735
[TBL] [Abstract][Full Text] [Related]
9. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.
Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH
Psychiatry Res; 2006 Nov; 144(2-3):177-89. PubMed ID: 17010448
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic medication adherence: is there a difference between typical and atypical agents?
Dolder CR; Lacro JP; Dunn LB; Jeste DV
Am J Psychiatry; 2002 Jan; 159(1):103-8. PubMed ID: 11772697
[TBL] [Abstract][Full Text] [Related]
11. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness.
Valenstein M; Kavanagh J; Lee T; Reilly P; Dalack GW; Grabowski J; Smelson D; Ronis DL; Ganoczy D; Woltmann E; Metreger T; Wolschon P; Jensen A; Poddig B; Blow FC
Schizophr Bull; 2011 Jul; 37(4):727-36. PubMed ID: 19933540
[TBL] [Abstract][Full Text] [Related]
12. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.
Leslie DL; Rosenheck RA
Am J Psychiatry; 2002 Sep; 159(9):1534-40. PubMed ID: 12202274
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
14. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia.
Hudson TJ; Owen RR; Thrush CR; Armitage TL; Thapa P
J Clin Psychiatry; 2008 Jan; 69(1):74-80. PubMed ID: 18312040
[TBL] [Abstract][Full Text] [Related]
15. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.
Valenstein M; Copeland LA; Owen R; Blow FC; Visnic S
J Clin Psychiatry; 2001 Jul; 62(7):545-51. PubMed ID: 11488366
[TBL] [Abstract][Full Text] [Related]
16. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders.
Dolder CR; Lacro JP; Jeste DV
Psychosom Med; 2003; 65(1):156-62. PubMed ID: 12554828
[TBL] [Abstract][Full Text] [Related]
17. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector.
Leslie DL; Rosenheck RA
J Ment Health Policy Econ; 2003 Sep; 6(3):113-21. PubMed ID: 14646004
[TBL] [Abstract][Full Text] [Related]
18. Dosing frequency and adherence to antipsychotic medications.
Pfeiffer PN; Ganoczy D; Valenstein M
Psychiatr Serv; 2008 Oct; 59(10):1207-10. PubMed ID: 18832509
[TBL] [Abstract][Full Text] [Related]
19. Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia.
Shafrin J; Schwartz TT; Lakdawalla DN; Forma FM
J Manag Care Spec Pharm; 2016 Nov; 22(11):1285-1291. PubMed ID: 27783545
[TBL] [Abstract][Full Text] [Related]
20. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
Jiang Y; Ni W
Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
